Ritter Pharmaceuticals to Present at the 28th Annual ROTH Conference
2016年3月10日 - 10:48PM
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a pharmaceutical company
developing novel therapeutic products that modulate the human gut
microbiome to treat gastrointestinal diseases, today announced that
Michael Step, Chief Executive Officer, will present a corporate
overview at the 28th Annual ROTH Conference on Tuesday, March 15,
2016.
Event: 28th Annual ROTH
ConferenceDate: Tuesday, March 15,
2016Time: 12:30-1:00 p.m. PT
About Ritter PharmaceuticalsRitter
Pharmaceuticals, Inc. develops novel therapeutic products that
modulate the human gut microbiome to treat gastrointestinal
diseases. The Company is advancing human gut health research by
exploring the metabolic capacity of gut microbiota, and translating
the functionality of these microbiome modulators into safe and
effective applications. Their lead drug candidate, RP-G28, has the
potential to become the first FDA-approved drug for lactose
intolerance, a condition that affects more than one billion people
worldwide.
Investor Contact:
David Burke
dburke@theruthgroup.com
(646) 536-7009
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 9 2024 まで 10 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 10 2023 まで 10 2024
Real-Time news about Ritter Pharmaceuticals Inc (ナスダック市場): 0 recent articles
その他のニュース記事